Efficacy Evaluation and Biological Index Analysis of Vagus Nerve Protection Strategy in Improving Persistent Cough After Single-Port Thoracoscopic Pulmonary Segmentectomy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600121527

Enrollment

Unknown

Registered

2026-03-31

Start date

2026-03-31

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent cough after single-port thoracoscopic segmentectomy of the lung

Interventions

Trial Group:Single-port thoracoscopic segmentectomy with intentional preservation of neural branches from the vagus nerve to the lung during dissection of lymph node stations 10 (hilar) and 7 (subcari

Control Group:Single-port thoracoscopic segmentectomy following conventional practice without preservation of neural branches from the vagus nerve to the lung during dissection of lymph node stations

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years with normal cognitive function; 2. Tumor staged as Stage ?A; 3. Pulmonary nodule with maximum diameter of 7-20 mm and solid component proportion <=50%; 4. At least complete hilar lymph node dissection; 5. No surgical contraindications identified by preoperative examinations; 6. The surgical method is pulmonary segmentectomy.

Exclusion criteria

Exclusion criteria: 1. A history of pulmonary surgery; 2. Pleural adhesion with unclear identification of the pulmonary vagus nerve; 3. Intraoperative change of surgical method (e.g., lobectomy); 4. Other surgical procedures performed in addition to pulmonary segmentectomy; 5. No lymph node dissection performed; 6. Injury to the main trunk of the vagus nerve during mediastinal lymph node dissection.

Design outcomes

Primary

Measure	Time frame
Pulmonary function parameters (VC, FVC, FEV1, DLCO);Cough symptoms (Cough Symptom Score, NRS for lung cancer-related cough);Chest pain symptoms (Visual Analog Scale);Cough reflex sensitivity (cough latency, cough frequency);Quality of life (QOL) score;	—

Secondary

Measure	Time frame
Inflammatory cytokine levels (IL-6, IL-10, IL-4, TNF-a, TNF-?);Neurotransmitter levels (acetylcholine, neuropeptide ?, neuropeptide A/B);Key molecule expression in cholinergic pathway (ACh, AChE, a7nAChR);Molecular expression of cough receptors (TRPV1, TRPA1);Mucin level (MUC5AC);Proportion of inflammatory cells in sputum (eosinophils, neutrophils);Protein expression of signaling pathways (TLRs, NF-?B);	—

Measure

Time frame

Inflammatory cytokine levels (IL-6, IL-10, IL-4, TNF-a, TNF-?);Neurotransmitter levels (acetylcholine, neuropeptide ?, neuropeptide A/B);Key molecule expression in cholinergic pathway (ACh, AChE, a7nAChR);Molecular expression of cough receptors (TRPV1, TRPA1);Mucin level (MUC5AC);Proportion of inflammatory cells in sputum (eosinophils, neutrophils);Protein expression of signaling pathways (TLRs, NF-?B);

—

Countries

China

Contacts

Public ContactKan Qiwei

Meishan People's Hospital

646967480@qq.com+86 28 38025161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026